Spain is introducing a new system for co-payments on prescription medicines. The reform of the so-called “Copago farmacéutico” aims to distribute costs more fairly and provide financial relief, particularly for people on lower incomes and patients facing high medication expenses.
Spain Expat Press Editorial Team
by Marlon Gallego Bosbach
For millions of people in Spain, the way their medication costs are calculated is changing. The new regulation replaces the previous model, which was based on only a few income categories, with a more detailed system designed to better reflect each patient’s individual financial situation.
The reform applies to medicines that patients receive from pharmacies with a doctor’s prescription. Medicines administered directly in hospitals are not affected by the new regulation.
New system places greater emphasis on income levels
Until now, the level of medication co-payment in Spain was mainly determined by a limited number of income brackets. According to the government, this system meant that some patients with limited financial resources still faced a disproportionately high financial burden.
Under the new system, there are now several income groups. This is intended to ensure that patients’ contributions towards medication costs are more closely aligned with their actual financial circumstances.
The level of co-payment will in future be based on annual income:
People with an annual income of up to €9,000 will continue to pay 40% of their medication costs. However, their maximum monthly contribution will be capped at €8.23.
For those with an income between €9,000 and €18,000 per year, the co-payment rate will also remain at 40%. However, their monthly contribution will be capped at a maximum of €18.52.
For people with an annual income between €18,000 and €35,000, the co-payment rate will increase to 45%. The maximum monthly contribution for this group will be capped at €61.75.
For higher incomes, the changes are less significant. People earning between €35,000 and €60,000 per year will continue to pay 45%, while those with incomes between €60,000 and €100,000 will contribute 50% of the costs. Anyone earning more than €100,000 annually will continue to cover 60% of the expenses.
Pensioners benefit from adjusted contribution caps
The reform is particularly significant for pensioners, as older people often rely on several medications on a long-term basis.
In principle, the co-payment for many pensioners remains at 10% of the cost. However, the monthly contribution limits have been adjusted to prevent people with lower pensions from being overwhelmed by high medication expenses.
Pensioners on lower incomes will benefit from a reduced cap in the future. This is intended to prevent people with chronic illnesses from having to forgo essential medication for financial reasons.
Older patients are one of the main target groups of the reform, as they often account for a significant proportion of medication costs within the healthcare system.
Certain groups remain fully exempt
Even after the reform, several specially protected groups will continue to be exempt from medication co-payments. These include recipients of Spain’s minimum income scheme (Ingreso Mínimo Vital), people receiving non-contributory pensions, and unemployed individuals who are not entitled to unemployment benefits.
Also exempt are minors with recognised disabilities, as well as people whose illnesses are the result of recognised workplace accidents or occupational diseases.
With this measure, the Spanish government aims to ensure that particularly vulnerable groups within the population continue to have unrestricted access to essential medicines.
No additional steps required at the pharmacy
For patients, the transition is intended to be as straightforward as possible. When purchasing prescription medicines, no additional documents or proof of income will need to be provided.
Pharmacies will automatically access information from the regional healthcare systems and calculate the correct co-payment based on the stored data. Patients will therefore continue to receive their medicines as usual using their health card.
If an incorrect calculation occurs, affected patients can apply for a refund through the relevant health authority.
What does the change mean for foreigners in Spain?
Many foreign residents in Spain are also affected by the reform. People with official residency status and access to the Spanish healthcare system are generally subject to the same rules as Spanish citizens.
For people without official residency in Spain, the previous rules will largely remain in place. They will continue to pay a fixed share of their medication costs, but will also benefit from a monthly maximum limit in the future.
The exact application of the rules may vary depending on an individual’s personal circumstances and residency status.
Goal: Keeping medicines affordable
The Spanish government justifies the reform primarily as a way to make access to medicines fairer. In particular, it aims to protect people with chronic conditions from rising healthcare costs becoming a financial burden.
In Spain, the issue of medication co-payments has been an important topic for years. Critics have repeatedly argued that older people and patients with long-term illnesses in particular needed greater financial relief.
With the new system, the government aims to create a balance between financing the healthcare system and providing social protection for the population.
One of the biggest changes in Spain’s healthcare system
The reform of the “Copago farmacéutico” is one of the most significant changes to Spain’s medicines system in recent years. Although millions of patients do not need to take any action to switch over, they will notice the impact directly during their next visit to the pharmacy.
While people on lower incomes and those with high medication expenses will receive greater protection in the future, the level of cost-sharing for higher-income groups will largely remain unchanged.
With this reform, Spain is moving towards a more income-based model designed to make access to medicines socially fairer.
